Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02252380 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT02252380 · ClinicalTrials.gov record · last posted 2025-05-01

ExAblate Transcranial MRgFUS for the Management of Treatment-Refractory Movement Disorders

StatusActive, Not Recruiting
PhaseNot applicable
SponsorInSightec
Started2015-05
View on ClinicalTrials.gov ↗
Record status
This record was last updated May 1, 2025 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.
from the ClinicalTrials.gov record
The proposed study is to evaluate the effectiveness of ExAblate Transcranial MRgFUS as a tool for creating a unilateral lesion in the Vim thalamus or the globus pallidus (GPi) in patients with treatment-refractory symptoms of movement disorders.

Amendment record 10 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 10 times since 2014-09-29; most recent amendment 2025-04-30. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2020-01-06
Status change Recruiting→Active, Not Recruitingv7
2015-05-19
Status change Not Yet Recruiting→Recruitingv1
Trial Details
NCT Number NCT02252380
Lead Sponsor InSightec
Conditions Movement Disorders, Essential Tremor, Holmes Tremor, Parkinson's Disease, Wilson's Disease, Huntington's Disease, Dystonia, Tardive Dyskinesia +1 more
Enrollment 10 participants
Start Date 2015-05
Primary Completion 2026-06 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2025-05-01